# US 2008/0187545 A1 · Cytomegalovirus surface protein complex for use in vaccines and as a drug target

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187545 A1
- Document ID: US20080187545A1
- Status: Published application
- Kind: A1
- Application number: 11/810,578
- Filed: 2007-06-06
- Published: 2008-08-07
- Earliest claimed: 2006-06-07
- Assignees: The Trustees of Princeton University
- Inventors: Thomas Shenk; Dai Wang
- Web page: https://patentgrep.com/patent/US20080187545A1

## CPC

- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/12: Viral antigens
- A61P 31/22: for herpes viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 16/085: Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K 16/089: {Cytomegalovirus}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2710/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

## Claims

### Claim 1

An immunogenic composition comprising a pharmaceutically acceptable carrier and a complex of cytomegalovirus (CMV) proteins comprising pUL128 or pUL130 and, optionally, at least one other virus or cellular constituent of a CMV virion complex.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the other virus or cellular constituent of the virion complex is one or more of pUL131, gH, gL, or gB.

### Claim 3 (depends on 1)

The composition of claim 1, wherein multiple fragments of one or more of pUL128, pUL130, pUL131, gH, gL or gB are linked into one polypeptide chain.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the complex is produced by expression of a CMV genome encoding an attenuated CMV, wherein the attenuation does not affect formation of the complex.

### Claim 5

A subunit vaccine comprising a pharmaceutically acceptable carrier and at least one cytomegalovirus (CMV) protein or fragment thereof, selected from pUL128, pUL130, or a complex that includes pUL128 or pUL130, and, optionally, at least one other virus or cellular constituent of a CMV virion complex, wherein the vaccine induces an immune response against CMV in a recipient.

### Claim 6 (depends on 5)

The subunit vaccine of claim 5, wherein at least one protein of the complex is coupled to a carrier protein.

### Claim 7 (depends on 5)

The subunit vaccine of claim 5, wherein the protein, protein fragment or complex is expressed on the surface of an attenuated CMV virus particle.

### Claim 8 (depends on 5)

The subunit vaccine of claim 5, wherein the protein or fragment thereof is fused to one or more other proteins or fragments thereof present on the surface of the CMV virus particle.

### Claim 9

A nucleic acid vaccine comprising a pharmaceutically acceptable carrier and a vector comprising at least one nucleic acid molecule encoding a CMV protein or fragment thereof, selected from pUL128, pUL130, or a complex that includes pUL128 or pUL130, wherein the at least one nucleic acid molecule is expressed in a vaccine recipient, and wherein the expression product induces an immune response against CMV in the recipient.

### Claim 10 (depends on 9)

The nucleic acid vaccine of claim 9, comprising a non-CMV vector that expresses one or more of pUL128, pUL130, pUL131, gH, gL, or gB, or a fragment thereof.

### Claim 11 (depends on 10)

The nucleic acid vaccine of claim 10, wherein two or more of the fragments are expressed on a single polypeptide.

### Claim 12

Antibodies or epitope-binding fragments thereof, which specifically bind to a virus-coded protein from a CMV virion complex that includes pUL128 or pUL130, wherein the antibodies or epitope-binding fragments thereof inhibit binding of the CMV virion complex to a cellular receptor, or CMV infection of a cell, or both.

### Claim 13 (depends on 12)

The antibodies of claim 12, which specifically bind to pUL128.

### Claim 14 (depends on 13)

The antibodies of claim 13, which are polyclonal antibodies of antiserum having ATCC Accession No. PTA-8474.

### Claim 15 (depends on 13)

The antibodies of claim 13, which compete for binding to an epitope on pUL128 recognized by monoclonal antibodies produced by a hybridoma cell line having ATCC Accession No. PTA-8473.

### Claim 16 (depends on 13)

The antibodies of claim 13, which are monoclonal antibodies produced by a hybridoma cell line having ATCC Accession No. PTA-8473.

### Claim 17 (depends on 16)

A neutralizing binding partner of a CMV virion complex comprising pUL128, which comprises one or more virion binding sequences having 70% or greater identity to one or more complementarity determining regions (CDR) present in the monoclonal antibodies of claim 16.

### Claim 18 (depends on 12)

The antibodies of claim 12, which specifically bind to pUL130.

### Claim 19 (depends on 18)

The antibodies of claim 18, which compete for binding to an epitope on pUL130 recognized by monoclonal antibodies produced by a hybridoma cell line having ATCC Accession No. PTA-8472.

### Claim 20 (depends on 18)

The antibodies of claim 18, which are monoclonal antibodies produced by a hybridoma cell line having ATCC Accession No. PTA-8472.

### Claim 21 (depends on 20)

A neutralizing binding partner of a CMV virion complex comprising pUL130, which comprises one or more virion binding sequences having 70% or greater identity to a complementarity determining regions (CDR) present in the monoclonal antibodies of claim 20.

### Claim 22

A method of inhibiting CMV infection of endothelial or epithelial cells, comprising inhibiting binding of a CMV virion complex comprising pUL128 or pUL130 to the cells, thereby inhibiting the CMV infection.

### Claim 23 (depends on 22)

The method of claim 22, wherein the inhibiting of binding is accomplished by treating the cells with an antibody immunospecific for pUL128 or pUL130.

### Claim 24

A method for screening compounds for the ability to inhibit entry of CMV into host cells, the method comprising:
a) exposing host cells, in the presence or absence of a test compound, to or one or more cellular receptors of host cells to CMV virions or a component thereof selected from (i) pUL128 or a fragment thereof, (ii) pUL130 or fragment thereof, or (iii) a complex that includes pUL128 or pUL130, and, optionally, at least one other virus or cellular constituent of a CMV virion complex; and
b) determining if the test compound interferes with binding of the CMV virions or component thereof to the host cells or cellular receptors, wherein the interfering of the binding is indicative that the test compound is capable of inhibiting the entry of the CMV into the host cells.

### Claim 25 (depends on 24)

The method of claim 24, wherein the host cells are epithelial cells or endothelial cells.

### Claim 26 (depends on 24)

The method of claim 24, wherein the CMV virions are produced by expressing a virion encoding polynucleotide in cells transfected with a vector containing the polynucleotide.

### Claim 27 (depends on 26)

The method of claim 26, wherein the vector is BADrUL131.

### Claim 28 (depends on 24)

The method of claim 24, wherein a selected test compound capable of interfering with the binding of CMV or components thereof to the host cells or cellular receptors is subjected to a secondary screen comprising:
a) exposing the host cells to CMV virions in the presence or absence of the selected test compound; and
b) determining if the selected test compound inhibits one or more of (i) production of CMV proteins within the host cells; (ii) a cytopathic effect of CMV infection; or (iii) spread of virus proteins from cell to cell, the inhibition being further indicative that the test compound is capable of inhibiting the CMV infection.

### Claim 29

A method of screening compounds for their ability to neutralize human CMV infectivity of endothelial or epithelial cells, the method comprising:
a) exposing the epithelial or endothelial cells to CMV virions comprising a virion complex that includes pUL128 or pUL130, in the presence or absence of a test compound; and
b) determining if the test compound inhibits entry of the CMV into the host cells, the inhibition being indicative that the test compound is able to neutralize human CMV infectivity of the endothelial or epithelial cells.

### Claim 30 (depends on 29)

The method of claim 29, wherein the test compound is an antibody or epitope-binding fragment thereof, or a neutralizing binding partner of a CMV virion complex comprising pUL130 or pUL128.

### Claim 31 (depends on 29)

The method of claim 29, wherein the CMV virions are produced by expressing a virion encoding polynucleotide in cells transfected with a vector containing s a genome of a clinical isolate of CMV or of a laboratory strain of CMV that comprises, or that has been engineered to comprise a functional UL131-128 locus.

### Claim 32 (depends on 31)

The method of claim 31, wherein the vector is BADrUL131.

### Claim 33

A method of immunizing a patient against CMV infection by administering to the patient a substance that is:
a) an immunogenic composition comprising a pharmaceutically acceptable carrier and a complex of cytomegalovirus (CMV) proteins comprising pUL128 or pUL130 and, optionally, at least one other virus or cellular constituent of a CMV virion complex;
b) a subunit vaccine comprising a pharmaceutically acceptable carrier and at least one cytomegalovirus (CMV) protein or fragment thereof, selected from pUL128, pUL130, or a complex that includes pUL128 or pUL130, and, optionally, at least one other virus or cellular constituent of a CMV virion complex; or
c) a nucleic acid vaccine comprising a pharmaceutically acceptable carrier and a vector comprising at least one nucleic acid molecule encoding a CMV protein or fragment thereof, selected from pUL128, pUL130, or a complex that includes pUL128 or pUL130, wherein the at least one nucleic acid molecule is expressed in the patient; under conditions permitting the patient to develop an immune response to the substance or the proteins encoded by the substance.

### Claim 34

A method of diminishing a CMV infection in a patient, comprising administering to the patient antibodies or epitope-binding fragments thereof, which specifically bind to a virus-coded protein in a CMV virion complex that includes pUL128 or pUL130, wherein the antibodies or epitope-binding fragments thereof inhibit binding of the human CMV virion complex to a cellular receptor, or CMV infection of a cell, or both, thereby diminishing the CMV infection in the patient.
